SILVER SPRING, Md., April 9, 2012 /PRNewswire/ -- Sunpeaks Ventures, Inc. (OTC Bulletin Board: SNPK) (PINKSHEETS: SNPK) (the "Company" or "Sunpeaks Ventures") and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS") are pleased to announce that HDS has signed a Letter of Intent with PharmaLife® for placement of Clotamin® with leading pharmacies in the Russian Federation.

The Letter of Intent outlines the terms and conditions of a proposed transaction that could see Clotamin distributed by several pharmacy and retail chains in the Russian Federation, including product placement with leading wholesalers Imperia-Pharma, the Dr. Stoletov pharmacy chain (414 locations), and other small retail pharmacies associated with Imperia-Pharma. PharmaLife is also expected to secure timely product registration within the Russian Federation for Clotamin distribution and conduct local market research to support a successful product launch.

"Potential demand for Clotamin is worldwide and this Letter of Intent to export into the Russian marketplace is the first agreement intended to meet that international demand," stated Mackie A. Barch, CEO of Sunpeaks. "We look forward to working closely with PharmaLife and our new possible distributors to build market awareness and sales of Clotamin across Russia. If successful, the Company intends to utilize this expansion strategy to penetrate other international markets that share similar potential."

PharmaLife is a premier integrated total healthcare solution provider, combining the nation's leading healthcare services company with a retail pharmacy chain. With over 10 years of dynamic growth and experience, PharmaLife delivers pharmaceutical services to thousands of clients and also provides business development and consulting services to assist other healthcare professionals reach their goals.

About Sunpeaks Ventures, Inc.

Sunpeaks Ventures, Inc. and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS"), is a nationally focused, value-added distributor of specialty drugs and over-the-counter ("OTC") branded multivitamins to the healthcare provider market. HDS also owns and markets Clotamin®, a specialized over-the-counter multivitamin product designed exclusively for use by patients also on Warfarin®, a popular blood thinner that has a long list of known adverse drug and food interactions.

For additional information, please visit www.sunpeaksventures.com.

Contact: Financial Insights 888-248-8491 or info@sunpeaksventures.com
Mackie Barch
202-270-5404

Safe Harbor Statement

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Sunpeaks Ventures' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Sunpeaks Ventures' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Sunpeaks Ventures herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Sunpeaks Ventures disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

SOURCE Sunpeaks Ventures, Inc.

SILVER SPRING, Md., April 4, 2012 /PRNewswire/ -- Sunpeaks Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) (the "Company" or "Sunpeaks Ventures") and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS") are pleased to announce that HDS has signed a marketing and distribution agreement with Asian American Convenience Store Association Partners and Skyrock ("AACSA Partners/Skyrock") to distribute and sell Clotamin in 1,200 AACSA member locations, including convenience stores, pharmacies, and small grocers. If successful, the parties anticipate expanding the initial program nationwide up to 10,000 additional locations. This Agreement will continue in effect for three (3) years.

"This is a milestone agreement for the Company and a huge leap forward for widespread Clotamin availability. Our agreement with AACSA/Skyrock can quickly place Clotamin in potentially thousands of hard-to-reach locations across the country," stated Mackie A. Barch, CEO of Sunpeaks Ventures. "In addition to the distribution, AACSA will market Clotamin to its members and its sister group of Asian American and Indian physicians. Reaching this highly fragmented, yet extremely influential group is near impossible without the help of a strong industry partner. By leveraging AACSA/Skyrock's established relationships with its member stores, we should be able to rapidly penetrate this market on a large scale."

The Asian American Convenience Stores Association ("AACSA") is an industry trade association representing thousands of stores nationwide. AACSA has been an advocate for the convenience retailing industry providing industry information, knowledge and connections to ensure the competitive viability of member businesses. AACSA has approximately 50,000 affiliate members. The convenience retail sector has undergone significant growth over the past three decades; ten years ago, the official industry store count stood at 100,800; 20 years ago there were 76,200 stores; and 30 years ago there were only 24,300. Today, the U.S. convenience store industry is comprised of nearly 145,000 stores which posted $511 billion in total sales in 2009.

About Sunpeaks Ventures, Inc.

Sunpeaks Ventures, Inc. and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS"), is a nationally focused, value-added distributor of specialty drugs and over-the-counter ("OTC") branded multivitamins to the healthcare provider market. HDS also owns and markets Clotamin®, a specialized over-the-counter multivitamin product designed exclusively for use by patients also on Warfarin®, a popular blood thinner that has a long list of known adverse drug and food interactions.

For additional information, please visit www.sunpeaksventures.com.

Contact: Financial Insights 888-248-8491 or info@sunpeaksventures.com
Mackie Barch
202-270-5404

Safe Harbor Statement

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Sunpeaks Ventures' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Sunpeaks Ventures' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Sunpeaks Ventures herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Sunpeaks Ventures disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

SOURCE Sunpeaks Ventures, Inc.

SILVER SPRING, Md., April 2, 2012 /PRNewswire/ -- Sunpeaks Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) (the "Company" or "Sunpeaks") and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS") are pleased to announce that the Company has entered into a strategic sales and marketing agreement with Acosta Sales & Marketing ("Acosta"), one of the leading sales and marketing agencies in the consumer packaged goods industry.

"This is a major accomplishment for Clotamin. One only needs to look at the long list of recognized brands that Acosta currently represents to get an idea of why we wanted to partner with them as our strategic sales and marketing firm," statedMackie A. Barch, CEO of Sunpeaks. "Acosta has a long established track record of helping to grow products into major national brands. We look forward to working with them to introduce Clotamin to new retailers and potential consumers across the country."

Acosta represents thousands of the most important brands in the United States and has developed relationships with many of the nation's largest retailers. Acosta has over $50 billion in system wide annual sales and close to 20,000 associates that call on over 100,000 retail stores per month. Acosta represents more #1 and #2 brands in North America than any other agency. Current Acosta clients range from Campbell's to Procter & Gamble, and retail customers range from Giant to Walmart.

About Sunpeaks Ventures, Inc.

Sunpeaks Ventures, Inc. and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS"), is a nationally focused, value-added distributor of specialty drugs and over-the-counter ("OTC") branded multivitamins to the healthcare provider market. HDS also owns and markets Clotamin®, a specialized over-the-counter multivitamin product designed exclusively for use by patients also on Warfarin®, a popular blood thinner that has a long list of known adverse drug and food interactions.

For additional information, please visit www.sunpeaksventures.com.

Contact: Financial Insights 888-248-8491 or info@sunpeaksventures.com
Mackie Barch
202-270-5404

Safe Harbor Statement

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Sunpeaks Ventures' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Sunpeaks Ventures' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Sunpeaks Ventures herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Sunpeaks Ventures disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

SOURCE Sunpeaks Ventures, Inc.

SILVER SPRING, Md., March 30, 2012 /PRNewswire/ -- Sunpeaks Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) (the "Company" or "Sunpeaks Ventures") and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS") are pleased to announce that Clotamin® is now an authorized product at Winn- Dixie. Clotamin will be available at 57 Winn- Dixie locations in South Florida starting in May 2012.

Winn- Dixie is headquartered in Jacksonville, Florida, and currently operates 482 stores throughout Alabama, Florida,Georgia, Louisiana and Mississippi. In addition to filling prescriptions, Winn- Dixie pharmacies also provide preventive health screenings, medication counseling, immunizations, and other services.

" Winn- Dixie stores have a long history in Florida and have built close ties within the communities they serve. We expect that their pharmacies will make an excellent venue for showcasing Clotamin and reach their many loyal customers," stated Mackie A. Barch, CEO of Sunpeaks. "Moving forward, we believe that our success at increasing distribution inFlorida will serve as a template for expanding Clotamin sales in other regions and also nationwide."

Clotamin® is the world's first specialized OTC multivitamin product designed exclusively for use by patients on Warfarin® or other anticoagulants (blood thinners).

About Sunpeaks Ventures, Inc.

Sunpeaks Ventures, Inc. and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS"), is a nationally focused, value-added distributor of specialty drugs and over-the-counter ("OTC") branded multivitamins to the healthcare provider market. HDS also owns and markets Clotamin®, a specialized over-the-counter multivitamin product designed exclusively for use by patients also on Warfarin®, a popular blood thinner that has a long list of known adverse drug and food interactions.

For additional information, please visit www.sunpeaksventures.com.

Contact: Financial Insights 888-248-8491 or info@sunpeaksventures.com
Mackie Barch
202-270-5404

Safe Harbor Statement

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Sunpeaks Ventures' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Sunpeaks Ventures' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Sunpeaks Ventures herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Sunpeaks Ventures disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

SOURCE Sunpeaks Ventures, Inc.

SILVER SPRING, Md., March 27, 2012 /PRNewswire/ -- Sunpeaks Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) (the "Company" or "Sunpeaks Ventures") and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS") are pleased to announce that the new television advertising campaign featuring Clotamin® will initially be aired nationwide on select cable stations including CNN, Headline News, MSNBC, Lifetime, Discovery, and others. This will be the first national television marketing campaign undertaken to raise brand awareness of Clotamin.

"Getting national exposure is critical to building customer awareness and growing sales," stated Mackie A. Barch, CEO of Sunpeaks. "The new Clotamin national advertising campaign is designed to push the brand into new markets. We couldn't be more excited for our many shareholders, customers, and potential customers."

The first Clotamin television spot has been created by Steve Procko Productions, a full service production company specializing in television commercials, infomercials, direct-response commercials, and corporate videos. The commercial is expected to premiere on select cable stations throughout the United States starting on April 2, 2012. This commercial was paid for by the Company as part of its national Clotamin marketing budget. For a sneak preview of the commercial, please visit the Sunpeaks Ventures website at www.sunpeaksventures.com/tvspots.html

Clotamin® is the world's first specialized OTC multivitamin product designed exclusively for use by patients on Warfarin® or other anticoagulants (blood thinners).

About Sunpeaks Ventures, Inc.

Sunpeaks Ventures, Inc. and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS"), is a nationally focused, value-added distributor of specialty drugs and over-the-counter ("OTC") branded multivitamins to the healthcare provider market. HDS also owns and markets Clotamin®, a specialized over-the-counter multivitamin product designed exclusively for use by patients also on Warfarin®, a popular blood thinner that has a long list of known adverse drug and food interactions.

For additional information, please visit www.sunpeaksventures.com.

Contact: Financial Insights 888-248-8491 or info@sunpeaksventures.com
Mackie Barch
202-270-5404

Safe Harbor Statement

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Sunpeaks Ventures' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Sunpeaks Ventures' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Sunpeaks Ventures herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Sunpeaks Ventures disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

SOURCE Sunpeaks Ventures, Inc.

SILVER SPRING, Md., March 26, 2012 /PRNewswire via COMTEX/ -- Sunpeaks Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) (the "Company" or "Sunpeaks Ventures") and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS") is pleased to announce that Clotamin will be available at select Bravo Supermarkets in South Florida in the next few weeks.
"We believe that the addition of Bravo Supermarkets to the growing list of retailers carrying Clotamin is another step toward complete patient coverage in the Florida region," stated Mackie A. Barch, CEO of Sunpeaks. "The expansion of distribution in Florida will continue to play a vital role in demonstrating the demand and market potential of Clotamin to both regional and national retailers going forward."

Clotamin is the world's first specialized OTC multivitamin product designed exclusively for use by patients on Warfarin or other anticoagulants (blood thinners).

About Sunpeaks Ventures, Inc.

Sunpeaks Ventures, Inc. and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS"), is a nationally focused, value-added distributor of specialty drugs and over-the-counter ("OTC") branded multivitamins to the healthcare provider market. HDS also owns and markets Clotamin, a specialized over-the-counter multivitamin product designed exclusively for use by patients also on Warfarin, a popular blood thinner that has a long list of known adverse drug and food interactions.

About Sunpeaks Ventures, Inc.

Sunpeaks Ventures, Inc. and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS"), is a nationally focused, value-added distributor of specialty drugs and over-the-counter ("OTC") branded multivitamins to the healthcare provider market. HDS also owns and markets Clotamin®, a specialized over-the-counter multivitamin product designed exclusively for use by patients also on Warfarin®, a popular blood thinner that has a long list of known adverse drug and food interactions.

For additional information, please visit www.sunpeaksventures.com.

Contact: Financial Insights 888-248-8491 or info@sunpeaksventures.com
Mackie Barch
202-270-5404

Safe Harbor Statement

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Sunpeaks Ventures' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Sunpeaks Ventures' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Sunpeaks Ventures herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Sunpeaks Ventures disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

SOURCE Sunpeaks Ventures, Inc.

SILVER SPRING, Md., March 23, 2012 /PRNewswire via COMTEX/ -- Sunpeaks Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) (the "Company" or "Sunpeaks Ventures") and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS") are pleased to announce that Clotamin will be starting a national advertising campaign. This will be the first national consumer driven marketing campaign undertaken to raise brand awareness of Clotamin.
"Until now, Clotamin has never been the focus of any consumer marketing. The product's popularity has been built solely through positive word of mouth from our customers and through pharmacies that already carry the product," stated Mackie A. Barch, CEO of Sunpeaks.

The first Clotamin television spot is being created by Steve Procko Productions, a full service production company specializing in television commercial production, infomercials, direct-response commercials, and corporate videos. The commercial is expected to premiere on select cable stations throughout the United States on April 2, 2012. We paid for the commercial as part of our marketing budget. For a sneak preview of the commercial, please visit the Sunpeaks Ventures website at www.sunpeaksventures.com/tvspots.html

Clotamin is the world's first specialized OTC multivitamin product designed exclusively for use by patients on Warfarin or other anticoagulants (blood thinners).

About Sunpeaks Ventures, Inc.

Sunpeaks Ventures, Inc. and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS"), is a nationally focused, value-added distributor of specialty drugs and over-the-counter ("OTC") branded multivitamins to the healthcare provider market. HDS also owns and markets Clotamin, a specialized over-the-counter multivitamin product designed exclusively for use by patients also on Warfarin, a popular blood thinner that has a long list of known adverse drug and food interactions.

For additional information, please visit www.sunpeaksventures.com.

Contact: Financial Insights 888-248-8491 or info@sunpeaksventures.com
Mackie Barch
202-270-5404

Safe Harbor Statement

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Sunpeaks Ventures' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Sunpeaks Ventures' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Sunpeaks Ventures herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Sunpeaks Ventures disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

SOURCE Sunpeaks Ventures, Inc.

SILVER SPRING, Md., March 21, 2012 /PRNewswire/ -- Sunpeaks Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) (the "Company" or "Sunpeaks Ventures") and its wholly owned subsidiary Healthcare Distribution Specialist, LLC ("HDS") are pleased to announce that the Company will be participating in the Diet, Vitamin & Sports Nutrition Expo to be held at the Westin Beach Resort & Spa in Fort Lauderdale, Florida on July 15-17, 2012. As part of the expo, HDS is scheduled to conduct one-on-one meetings and planning sessions with national pharmacies and retailers, including Costco, CVS, GNC, Kmart, Vitamin World, and many others.

"Participating in this event is going to give us one-on-one time with numerous companies. Given the amount of Warfarin that is sold through these companies, it is our belief they will be able to understand the value proposition of carrying Clotamin in their stores," stated Mackie A. Barch, CEO of Sunpeaks. "Although Clotamin already has a nationwide distribution footprint, the potential addition of these key players can only increase product awareness and continue to build sales and shareholder value."

The Diet, Vitamin & Sports Nutrition Expo is organized by Efficient Collaborative Retail Marketing ("ECRM"), a provider of business solutions by integrating process, vision and technology. Comprised of Efficient Program Planning Sessions ("EPPS"), a powerful website, and the MarketGate Application Suite™ software, ECRM® helps retailers and manufacturers improve sales, reduce expenses and go to market faster and more efficiently.

EPPS category-specific events consist of one-on-one planning sessions scheduled between manufacturers, retailers and distributors to review new items, marketing initiatives, and strategic direction. Each manufacturer is provided a hotel suite to set up products, displays and related materials and to hold meetings.

About Sunpeaks Ventures, Inc.

Sunpeaks Ventures, Inc. and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS"), is a nationally focused, value-added distributor of specialty drugs and over-the-counter ("OTC") branded multivitamins to the healthcare provider market. HDS also owns and markets Clotamin®, a specialized over-the-counter multivitamin product designed exclusively for use by patients also on Warfarin®, a popular blood thinner that has a long list of known adverse drug and food interactions.

For additional information, please visit www.sunpeaksventures.com.

Contact: Financial Insights 888-248-8491 or info@sunpeaksventures.com
Mackie Barch
202-270-5404

Safe Harbor Statement

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Sunpeaks Ventures' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Sunpeaks Ventures' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Sunpeaks Ventures herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Sunpeaks Ventures disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

SOURCE Sunpeaks Ventures, Inc.

SILVER SPRING, Md., March 20, 2012 /PRNewswire/ -- Sunpeaks Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) (the "Company" or "Sunpeaks Ventures") and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS") are pleased to announce that Clotamin® will soon be available at Navarro Discount Pharmacies locations across South Florida.

Founded in 1940, Navarro Discount Pharmacies, Inc. is one of the largest Hispanic-owned pharmacy chains, photo services, and pharmacy benefit managers in the United States. Navarro currently operates 31 pharmacy stores mainly inMiami-Dade and Broward Counties, Florida. The company has more than 2,000 employees and annual sales of more than $350 million. Navarro also leads the industry in terms of sales per store, sales per square foot, and prescriptions filled per store.

"We believe that Navarro is the leader of their regional pharmacy market and the inclusion of Clotamin to their shelves is another step toward our product reaching the entire South Florida territory," stated Mackie A. Barch, CEO of Sunpeaks.

Clotamin® is the world's first specialized OTC multivitamin product designed exclusively for use by patients on Warfarin® or other anticoagulants (blood thinners). According to BioMed Trends, in a report released by Global Industry Analysts, Inc., the global anticoagulants market is projected to surpass $11.2 billion by the year 2015, driven by an aging global population, rising incidence of cardiovascular diseases, cancers, and acute hip and knee complications, as well as emergence of innovative therapeutics targeting new and previously targeted clotting factors.

About Sunpeaks Ventures, Inc.

Sunpeaks Ventures, Inc. and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS"), is a nationally focused, value-added distributor of specialty drugs and over-the-counter ("OTC") branded multivitamins to the healthcare provider market. HDS also owns and markets Clotamin®, a specialized over-the-counter multivitamin product designed exclusively for use by patients also on Warfarin®, a popular blood thinner that has a long list of known adverse drug and food interactions.

For additional information, please visit www.sunpeaksventures.com.

Contact: Financial Insights 888-248-8491 or info@sunpeaksventures.com
Mackie Barch
202-270-5404

Safe Harbor Statement

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Sunpeaks Ventures' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Sunpeaks Ventures' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Sunpeaks Ventures herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Sunpeaks Ventures disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

SOURCE Sunpeaks Ventures, Inc.

SILVER SPRING, Md., March 19, 2012 /PRNewswire/ -- Sunpeaks Ventures, Inc. (OTC Bulletin Board: SNPK) (PINKSHEETS: SNPK) (the "Company" or "Sunpeaks Ventures") and its wholly owned subsidiary Healthcare Distribution Specialist, LLC ("HDS") are pleased to announce that Clotamin® is now available on Walgreens.com.

"The addition of Walgreens.com is an important step for the distribution of Clotamin. Clotamin has a significant market to reach and this is just another step in the process," stated Mackie A. Barch, CEO of Sunpeaks. "We couldn't be more excited to have our product available on Walgreens.com."

Clotamin® is the world's first specialized OTC multivitamin product designed exclusively for use by patients on Warfarin® or other anticoagulants (blood thinners). According to BioMed Trends, in a report released by Global Industry Analysts, Inc., the global anticoagulants market is projected to surpass $11.2 billion by the year 2015, driven by an aging global population, rising incidence of cardiovascular diseases, cancers, and acute hip and knee complications, as well as emergence of innovative therapeutics targeting new and previously targeted clotting factors.

About Sunpeaks Ventures, Inc.

Sunpeaks Ventures, Inc. and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS"), is a nationally focused, value-added distributor of specialty drugs and over-the-counter ("OTC") branded multivitamins to the healthcare provider market. HDS also owns and markets Clotamin®, a specialized over-the-counter multivitamin product designed exclusively for use by patients also on Warfarin®, a popular blood thinner that has a long list of known adverse drug and food interactions.

For additional information, please visit www.sunpeaksventures.com.

Contact: Financial Insights 888-248-8491 or info@sunpeaksventures.com
Mackie Barch
202-270-5404

Safe Harbor Statement

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Sunpeaks Ventures' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Sunpeaks Ventures' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Sunpeaks Ventures herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Sunpeaks Ventures disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

SOURCE Sunpeaks Ventures, Inc.

SILVER SPRING, Md., March 16, 2012 /PRNewswire/ -- Sunpeaks Ventures, Inc. (OTCBB: SNPK) announces that it has initiated a review, through special outside counsel, in connection with the high volume of trading and price rise in its common shares on the OTC Bulletin Board.

The trading did not involve any shares held by current Sunpeaks officers, directors, insiders or employees, as Mr. Barch is the only insider who is a shareholder. All of Mr. Barch's shares are restricted from trading under applicable federal securities laws. Preliminary indications are that the recent trading activity was conducted by persons unknown to current management.

Sunpeaks welcomes that FINRA has commenced promptly an inquiry into the trading, and the Company and Mr. Barch are cooperating fully with the inquiry. FINRA is the largest independent regulator for all securities firms doing business in the United States, overseeing brokerage firms branch offices and registered securities representatives. Sunpeaks and Mr. Barch stand fully behind the accuracy and content of all press releases issued by the Company since February 29, 2012.

Sunpeaks also has become aware that internet newsletters have been making unsupportable claims, inappropriate comparisons and unjustifiable common stock performance projections about the Company. The Company has not, does not and will not communicate with publishers of internet newsletters about OTC Bulletin Board stocks. Moreover, neither the Company nor anyone associated with the Company has paid anyone to promote its securities. Sunpeaks refers all potential investors to a warning issued by the US Securities and Exchange Commission about potentially misleading conduct in the promotion of stocks via the internet. Consistent with the SEC's investor notice, Sunpeaks cautions potential investors who are interested in information about the Company to consider only information issued directly by the Company in filings with the SEC and press releases published by the Company.

The Company expressly disclaims any obligation in the future to address in public announcements or otherwise unusual patterns of trading in its common stock or unusual prices or price swings thereof.

About Sunpeaks Ventures, Inc.

Sunpeaks Ventures, Inc. and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS"), is a nationally focused, value-added distributor of specialty drugs and over-the-counter ("OTC") branded multivitamins to the healthcare provider market. HDS also owns and markets Clotamin®, a specialized over-the-counter multivitamin product designed exclusively for use by patients also on Warfarin®, a popular blood thinner that has a long list of known adverse drug and food interactions.

For additional information, please visit www.sunpeaksventures.com.

Contact: Financial Insights 888-248-8491 or info@sunpeaksventures.com
Mackie Barch
202-270-5404

Safe Harbor Statement

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Sunpeaks Ventures' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Sunpeaks Ventures' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Sunpeaks Ventures herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Sunpeaks Ventures disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

SOURCE Sunpeaks Ventures, Inc.

SILVER SPRING, Md., March 17, 2012 /PRNewswire/ -- Sunpeaks Ventures, Inc.'s (OTCBB: SNPK) (PINKSHEETS: SNPK) (the "Company" or "Sunpeaks Ventures") wholly owned subsidiary Healthcare Distribution Specialist, LLC ("HDS") is pleased to announce that they have entered into an agreement with former All-Star player and professional basketball coach, Paul Silas, as national spokesperson for Clotamin®. Clotamin is the world's first specialized OTC multivitamin product designed exclusively for use by patients on Warfarin® and other anticoagulants (blood thinners).

Coach Silas is currently a professional basketball head coach and nominee for the Naismith Basketball Hall of Fame Class of 2012. During his 15+ year professional playing career, Silas collected more than 10,000 points and 10,000 rebounds, won three championship rings, and was twice named to the All-Star team. He ranks in the Top 20 for career games played, rebounding, and playoff rebounding. Since his retirement from active play, Paul has spent time as a popular professional basketball television commentator and as head coach with several professional basketball teams.

"We couldn't be happier about having Paul as part of our team. We noticed his name when we were shipping his Clotamin and reached out to him about working with us and he couldn't have been nicer," stated Mackie A. Barch, CEO of Sunpeaks. "We plan to launch a ad campaign featuring Paul to help drive Clotamin into new markets and distribution channels."

About Sunpeaks Ventures, Inc.
Sunpeaks Ventures, Inc. and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS"), is a nationally focused, value-added distributor of specialty drugs and over-the-counter ("OTC") branded multivitamins to the healthcare provider market. HDS also owns and markets Clotamin®, a specialized over-the-counter multivitamin product designed exclusively for use by patients also on Warfarin®, a popular blood thinner that has a long list of known adverse drug and food interactions.

Contact: Financial Insights 888-248-8491 or info@sunpeaksventures.com
Mackie Barch
202-270-5404

Safe Harbor Statement
Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Sunpeaks Ventures' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Sunpeaks Ventures' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Sunpeaks Ventures herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Sunpeaks Ventures disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

SOURCE Sunpeaks Ventures, Inc.

SILVER SPRING, Md., March 7, 2012 /PRNewswire/ -- Sunpeaks Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) (the "Company" or "Sunpeaks Ventures"), value-added distributor of specialty drugs and over-the-counter ("OTC") branded multivitamins to the healthcare provider market, is pleased to announce that it has forwarded all necessary documentation to the company's transfer agent to cancel 50,000,000 common shares of the Company's stock with the intent of improving the overall capital structure and to increase shareholder value. The cancelled shares were previously held by Mr. Mackie A. Barch, CEO of Sunpeaks.

The share cancellation reduces the total number of issued and outstanding shares from 420,500,750 to 370,500,750.

About Sunpeaks Ventures, Inc.

Sunpeaks Ventures, Inc. and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS"), is a nationally focused, value-added distributor of specialty drugs and over-the-counter ("OTC") branded multivitamins to the healthcare provider market. HDS also owns and markets Clotamin®, a specialized over-the-counter multivitamin product designed exclusively for use by patients also on Warfarin®, a popular blood thinner that has a long list of known adverse drug and food interactions.

For additional information, please visit www.sunpeaksventures.com.

Contact: Financial Insights 888-248-8491 or info@sunpeaksventures.com
Mackie Barch
202-270-5404

Safe Harbor Statement

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Sunpeaks Ventures' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Sunpeaks Ventures' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Sunpeaks Ventures herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Sunpeaks Ventures disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

SOURCE Sunpeaks Ventures, Inc.

SILVER SPRING, Md., March 7, 2012 /PRNewswire/ -- Sunpeaks Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) (the "Company" or "Sunpeaks Ventures") and its' wholly owned subsidiary Healthcare Distribution Specialist, LLC ("HDS") are pleased to provide this update regarding the development and market potential of Clotamin®, an OTC multivitamin product owned and marketed by the Company.

Clotamin® is the world's first specialized OTC multivitamin product designed exclusively for use by patients on Warfarin® or other anticoagulants (blood thinners). According to BioMed Trends, in a report released by Global Industry Analysts, Inc., the global anticoagulants market is projected to surpass $11.2 billion by the year 2015, driven by an aging global population, rising incidence of cardiovascular diseases, cancers, and acute hip and knee complications, as well as emergence of innovative therapeutics targeting new and previously targeted clotting factors.

"The Warfarin market is absolutely enormous, – in fact, it's one of the Top 20 most prescribed drugs in the United States, with over 32 million prescriptions being written each year for approximately 6 to 7 million patients," stated Mackie A. Barch, CEO of Sunpeaks and longtime Warfarin patient. "By my calculations, if Sunpeaks is able to penetrate just 5% of the Warfarin market in just the U.S., sales for Clotamin could potentially surpass $25 million dollars annually. We look forward to ramping up our marketing and distribution efforts over the next few weeks and increasing awareness of Clotamin nationwide."

About Sunpeaks Ventures, Inc.

Sunpeaks Ventures, Inc. and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS"), is a nationally focused, value-added distributor of specialty drugs and over-the-counter ("OTC") branded multivitamins to the healthcare provider market. HDS also owns and markets Clotamin®, a specialized over-the-counter multivitamin product designed exclusively for use by patients also on Warfarin®, a popular blood thinner that has a long list of known adverse drug and food interactions.

For additional information, please visit www.sunpeaksventures.com.

Contact: Financial Insights 888-248-8491 or info@sunpeaksventures.com

Safe Harbor Statement

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Sunpeaks Ventures' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Sunpeaks Ventures' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Sunpeaks Ventures herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Sunpeaks Ventures disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

SOURCE Sunpeaks Ventures, Inc.

SILVER SPRING, Md., March 6, 2012 /PRNewswire/ -- Sunpeaks Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) (the "Company" or "Sunpeaks Ventures") is pleased to provide this corporate update detailing the Company's business strategy.

Sunpeaks Ventures, through the recent acquisition of its wholly owned subsidiary Healthcare Distribution Specialists ("HDS"), has entered the specialty drug distribution sector. The U.S. pharmaceutical distribution sector is approximately a $300 billion dollar marketplace. Within this industry, the three largest drug wholesalers distribute more than 85% of all prescription medication in the United States. The remaining 15% represents a $45 billion distribution market for specialty pharmaceuticals. HDS's strategic goal is to become a significant player in this highly fractured secondary wholesale market.

"The hard-to-find and specialty drug sector is rapidly growing and HDS is positioned to become a potential leader in the secondary wholesale market," stated Mr. Mackie Barch, President and CEO of Sunpeaks Ventures. "With the addition of a veteran sales team, led by Matthew Swift, HDS has the industry experience and know how to gain market share quickly. If HDS only captures 0.1% of the market, we are looking at potential revenue in excess $45 million from the pharmaceutical distribution business alone. Based on the performance of Mr. Swift's teams in the past, we believe that we can do significantly better than that given our diversified business and investments in high-tech IT infrastructure. The opportunity that lies ahead of us is enormous."

In addition to the distribution business, the Company also owns and markets Clotamin®, the world's first specialized over-the-counter multivitamin product designed exclusively for use by patients on Warfarin® or other blood thinners. The wellbeing and lifestyle of patients prescribed these popular drugs are often compromised by their long list of known adverse drug and food interactions. Clotamin has been specifically developed and formulated to control and reduce these adverse interactions. There are over 32 million prescriptions written each year for Warfarin, which equates to millions of potential Clotamin users in the U.S. alone.

Mr. Barch went on to state, "Both myself and other members of my family have been affected by blood clots and have taken blood thinner medications, so our first hand experience has been a major driver in getting Clotamin to market. Warfarin is one of the most commonly prescribed medications in the world and the people using it do not have many options to supplement their already heavily restricted diet. We see an enormous market opportunity for Clotamin and other engineered OTC drugs that focus on various specific disease states. With only modest market penetration rate, we could realize significant revenue and profits."

About Sunpeaks Ventures, Inc.

Sunpeaks Ventures, Inc. and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS"), is a nationally focused, value-added distributor of specialty drugs and over-the-counter ("OTC") branded multivitamins to the healthcare provider market. HDS also owns and markets Clotamin®, a specialized over-the-counter multivitamin product designed exclusively for use by patients also on Warfarin®, a popular blood thinner that has a long list of known adverse drug and food interactions.

For additional information, please visit www.sunpeaksventures.com.

Contact: Financial Insights 888-248-8491 or info@sunpeaksventures.com
Mackie Barch 202-270-5404

Safe Harbor Statement

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Sunpeaks Ventures' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Sunpeaks Ventures' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Sunpeaks Ventures herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Sunpeaks Ventures disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

SOURCE Sunpeaks Ventures, Inc.

SILVER SPRING, Md., March 2, 2012 /PRNewswire/ -- Sunpeaks Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) (the "Company" or "Sunpeaks Venutres") is pleased to announce that it has completed an initial financing of $200,000. The proceeds from this financing will be used for general working capital and other such purposes as the Company may determine from time to time.

"The most important reason to become a publicly traded company is to access additional growth capital on more attractive terms," stated Mr. Mackie Barch, President and CEO of Sunpeaks Ventures. "This initial financing and future potential capital raises will fuel our corporate growth and help position the Company as leaders in the hard-to-find and specialty drug distribution sector."

Further updates regarding Sunpeaks Ventures and HDS will be made as additional information becomes available.

About Sunpeaks Ventures, Inc.

Sunpeaks Ventures, Inc. and its wholly owned subsidiary Healthcare Distribution Specialist, LLC ("HDS"), is a nationally focused, value-added distributor of specialty drugs and over-the-counter ("OTC") branded multivitamins to the healthcare provider market. HDS also owns and markets Clotamin®, a specialized over-the-counter multivitamin product designed exclusively for use by patients also on Warfarin®, a popular blood thinner that has a long list of known adverse drug and food interactions.

For additional information, please visit www.sunpeaksventures.com.

Contact: Financial Insights 888-248-8491 or info@sunpeaksventures.com

Safe Harbor Statement

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Sunpeaks Ventures' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Sunpeaks Ventures ' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Sunpeaks Ventures herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Sunpeaks Ventures disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

SOURCE Sunpeaks Ventures, Inc.
Mackie Barch 202-270-5404